A Phase 1/2, Open-label, Multicenter Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Anti-tumor Efficacy of DZD8586 in Patients with Relapsed or Refractory B-cell Non-Hodgkin Lymphoma (B-NHL)
Latest Information Update: 22 May 2025
At a glance
- Drugs Birelentinib (Primary)
- Indications B-cell lymphoma; Non-Hodgkin's lymphoma
- Focus Adverse reactions
- Acronyms TAI-SHAN1
- Sponsors Dizal Pharmaceutical
Most Recent Events
- 15 May 2025 According to a Dizal Pharmaceutical media release, data from this trial will be presented at the 2025 European Hematology Association (EHA) Congress and the 18th International Conference on Malignant Lymphoma (ICML),
- 01 Apr 2025 According to Dizal biopharma media release, results of its investigational drug candidates DZD8586 have been selected for presentation at the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting, taking place May 30-June 3, 2025, in Chicago.
- 21 Feb 2025 Status changed from recruiting to completed.